TriangleZanzalintinib (NCT07043608)
Zanzalintinib trial for Clear Cell Renal Cell Cancer (ccRCC) (NCT07043608). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced clear-cell-predominant kidney cancer, at least three bone metastases, and one to three prior treatment lines including qualifying checkpoint immunotherapy. At least one bone lesion must remain outside planned radiation.
The idea: zanzalintinib blocks growth and blood-vessel signaling. Patients take 100 milligrams orally daily, with a physician-selected bone-strengthening drug. Dental clearance is required. Symptom-directed radiation is optional. Researchers assess progression-free survival, bone complications, and safety.
This phase 2 study plans 20 patients. Kelly Fitzgerald leads at the University of California, San Francisco, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.